AGTC Applied Genetic Technologies Corporation

5.77
+0.17  (+3%)
Previous Close 5.6
Open 5.56
52 Week Low 2.29
52 Week High 10.42
Market Cap $148,667,633
Shares 25,765,621
Float 25,580,595
Enterprise Value $65,251,477
Volume 243,164
Av. Daily Volume 427,106
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
AGTC-501
X-linked Retinitis Pigmentosa (XLRP)
Phase 1/2
Phase 1/2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
AAV Gene Therapy
Achromatopsia
Phase 1/2
Phase 1/2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
rAAV-hRS1
X-linked retinoschisis (XLRS)
Phase 1/2
Phase 1/2
Phase 1/2 interim data released December 12, 2018. No signs of clinical activity.

Latest News

  1. Patient Advisory Council to include advocates from the inherited retinal diseases global community

     New Patient Advisory Council to focus initially on Company's clinical stage programs for X-linked retinitis pigmentosa (XLRP)

    GAINESVILLE, Fla., and CAMBRIDGE, Mass., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced the formation of a Patient Advisory Council to build on its focus of incorporating the patient and caregiver voice into the Company's culture and clinical and pre-clinical programs.

    Engagement with patients and caregivers has provided…

    Patient Advisory Council to include advocates from the inherited retinal diseases global community

     New Patient Advisory Council to focus initially on Company's clinical stage programs for X-linked retinitis pigmentosa (XLRP)

    GAINESVILLE, Fla., and CAMBRIDGE, Mass., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced the formation of a Patient Advisory Council to build on its focus of incorporating the patient and caregiver voice into the Company's culture and clinical and pre-clinical programs.

    Engagement with patients and caregivers has provided AGTC with substantive information that has guided its clinical trial design, enhanced its understanding of retinal disorders, and inspired its patient centric culture. The Council, spearheaded by Jill Dolgin, PharmD, Head of Patient Advocacy at AGTC, is comprised of individuals with inherited retinal diseases (IRDs) and members from the global community of organizations that represent them.

    "Patient engagement will continue to be a critical success factor for our programs moving forward, and we are very pleased to formalize the establishment of this distinguished group of patient experts, especially as we move into the next phase of development for our X-linked retinitis pigmentosa gene therapy candidate," said Sue Washer, President and CEO of AGTC.

    In July, AGTC announced next steps in the clinical development of the Company's potential treatment of XLRP caused by mutations in the RPGR gene following receipt of written feedback from the U.S. Food and Drug Administration. AGTC is expanding the ongoing Phase 1/2 trial to dose additional patients in two masked dosing arms to collect additional functional data. In parallel, a planned Phase 2/3 trial, which is expected to begin in Q1 2021, will be designed to evaluate sustained efficacy across multiple measures of potential benefit in patients with XLRP. 

    "We are delighted to be a part of this advisory council established by AGTC to lend our voice and collective experience that spans more than five decades in the search for treatments to address blindness and vision loss," said Brian Mansfield, PhD, Executive Vice President of Research and Interim Chief Scientific Officer at the Foundation Fighting Blindness. "Having the patient's perspective at the center of clinical drug development is a crucial component for addressing the unmet needs of patients within the inherited retinal diseases community."

    Organizations and advocate members of the Patient Advisory Council include:

    OrganizationNameTitle
    Foundation Fighting BlindnessBrian Mansfield, PhDExecutive Vice President of Research, Interim Chief Scientific Officer, and oversees the My Retina Tracker Registry patient database
     Todd Durham, PhDVice President, Clinical Outcomes Research
     Michelle GlazeAssociate Director, Professional Outreach, and an individual affected by retinitis pigmentosa (RP)
     Richard FaubionSenior Director, Development; individual affected by XLRP, and a stem cell transplant clinical trial participant
    Fighting Blindness CanadaShari Shaw, MHScHealth Information Officer, and an individual with RP
    Retina InternationalAvril DalyCEO; Vice President, Board of Directors of the European Organization for Rare Diseases (Eurordis), and an individual affected by RP
    Sofia Sees HopeLaura ManfreePresident and Founder, and parent of a child with Leber Congenital Amaurosis (LCA)
     Alison Lynch, JDDisabilities attorney, individual affected by achromatopsia, and non-gene therapy clinical trial participant

    About AGTC

    AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. The Company's most advanced clinical programs leverage its best-in-class investigational technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 & ACHM CNGA3). Its pre-clinical programs build on the Company's industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

    About X-linked Retinitis Pigmentosa (XLRP)

    XLRP is an inherited condition that causes progressive vision loss in boys and young men. Characteristics of the disease include night blindness in early childhood and progressive constriction of the visual field. In general, XLRP patients experience a gradual decline in visual acuity over the disease course, which results in legal blindness around the 4th decade of life. AGTC was granted U.S. Food and Drug Administration (FDA) orphan drug designation in 2017, as well as European Commission orphan medicinal product designation in 2016, for its gene therapy product candidate to treat XLRP caused by mutations in the RPGR gene.

    Forward-Looking Statements

    This release contains forward-looking statements that reflect AGTC's plans, estimates, assumptions and beliefs, including statements regarding the timing for and expected expansion of its XLRP clinical development program, the timing for reporting data in its XLRP and ACHM clinical programs, and its ability to enroll patients, effectively design and successfully complete its ongoing clinical trials. Forward-looking statements include information concerning possible or assumed preclinical and clinical product development and regulatory progress, future results of operations, financial guidance, business strategies and operations, potential growth opportunities, potential market opportunities, the effects of competition and the impact of the COVID-19 pandemic. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" or similar expressions and the negatives of those terms. Actual results could differ materially from those discussed in the forward-looking statements, due to a number of important factors. Risks and uncertainties that may cause actual results to differ materially include, among others: gene therapy is still novel with only a few approved treatments so far; AGTC cannot predict when or if it will obtain regulatory approval to commercialize a product candidate or receive reasonable reimbursement; uncertainty inherent in clinical trials and the regulatory review process; risks and uncertainties associated with drug development and commercialization; the direct and indirect impacts of the ongoing COVID-19 pandemic on the Company's business, results of operations, and financial condition; factors that could cause actual results to differ materially from those described in the forward-looking statements are set forth under the heading "Risk Factors" in the Company's most recent annual or quarterly report and in other reports AGTC has filed with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent management's plans, estimates, assumptions and beliefs only as of the date of this release. Except as required by law, AGTC assumes no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

    IR/PR CONTACTS: 

    David Carey (IR) or Glenn Silver (PR)

    Lazar FINN Partners

    T: (212) 867-1768 or (646) 871-8485

    or

    Corporate Contact:

    Bill Sullivan

    Chief Financial Officer

    Applied Genetic Technologies Corporation

    T: (617) 843-5728

    Stephen Potter

    Chief Business Officer

    Applied Genetic Technologies Corporation

    T: (617) 413-2754

     

    Primary Logo

    View Full Article Hide Full Article
  2. Washington D.C--(Newsfile Corp. - August 4, 2020) - At today’s meeting of the Small Business Capital Formation Advisory Committee, the Securities and Exchange Commission announced the appointment of two new members to the Committee:

    • Kesha Cash, Founder and General Partner, Impact America Fund
    • Sue Washer, President and CEO, Applied Genetic Technologies Corporation (NASDAQ:AGTC)

    The new members were appointed following the resignations of Terry McNew, former President and CEO of Mastercraft Boat Holdings, and Karen Mills, President of MMP Group Inc.

    “Kesha and Sue each bring a wealth of expertise and fresh perspectives regarding capital raising for emerging companies, and they will be valuable additions to our outstanding Committee,” said…

    Washington D.C--(Newsfile Corp. - August 4, 2020) - At today’s meeting of the Small Business Capital Formation Advisory Committee, the Securities and Exchange Commission announced the appointment of two new members to the Committee:

    • Kesha Cash, Founder and General Partner, Impact America Fund
    • Sue Washer, President and CEO, Applied Genetic Technologies Corporation (NASDAQ:AGTC)

    The new members were appointed following the resignations of Terry McNew, former President and CEO of Mastercraft Boat Holdings, and Karen Mills, President of MMP Group Inc.

    “Kesha and Sue each bring a wealth of expertise and fresh perspectives regarding capital raising for emerging companies, and they will be valuable additions to our outstanding Committee,” said Martha Miller, the SEC’s Advocate for Small Business Capital Formation and Committee Member.  “We will miss Terry and Karen, and we thank them for their service and commitment to supporting small businesses and their investors.”

    In addition, the Committee recently welcomed Melanie Senter Lubin, Maryland Securities Commissioner, as the representative of the North American Securities Administrators Association, and William Manger, Associate Administrator for the Office of Capital Access, as the representative of the U.S. Small Business Administration, each of whom was appointed by their respective organization to serve in non-voting capacities.

    The Committee was established by the SEC Small Business Advocate Act of 2016, and is designed to provide a formal mechanism for the Commission to receive advice and recommendations on Commission rules, regulations, and policy matters relating to small businesses, including smaller public companies.  The Committee meets virtually today, August 4, to focus on how capital markets are serving underrepresented founders.  The meeting takes place from 10 a.m. through 3 p.m. ET and is webcast live on the Commission’s website.

    View Full Article Hide Full Article
  3. GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President & Chief Executive Officer, will present at the Wedbush PacGrow Virtual Healthcare Conference on Tuesday, August 11, 2020 at 10:20 am ET.

    A live audio webcast of the presentation will be available by visiting http://ir.agtc.com/events-and-presentations. A replay will be available on the Company's website following the event.

    About AGTC
    AGTC is a clinical-stage biotechnology company developing genetic therapies for people with…

    GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President & Chief Executive Officer, will present at the Wedbush PacGrow Virtual Healthcare Conference on Tuesday, August 11, 2020 at 10:20 am ET.

    A live audio webcast of the presentation will be available by visiting http://ir.agtc.com/events-and-presentations. A replay will be available on the Company's website following the event.

    About AGTC

    AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. Initially focusing on ophthalmology, we are leveraging our best-in-class investigational technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 & ACHM CNGA3). Our pre-clinical programs build on our industry leading AAV manufacturing technology and expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

    IR/PR CONTACTS: 

    David Carey (IR) or Glenn Silver (PR)

    Lazar FINN Partners

    T: (212) 867-1768 or (646) 871-8485

    or

    Corporate Contact:

    Bill Sullivan

    Chief Financial Officer

    Applied Genetic Technologies Corporation

    T: (617) 843-5728

    Stephen Potter

    Chief Business Officer

    Applied Genetic Technologies Corporation

    T: (617) 413-2754

    Primary Logo

    View Full Article Hide Full Article
  4. FDA feedback allows for forward program development

    Company reiterates that its favorable safety profile and its advanced manufacturing and analytics capabilities enable rapid clinical development

    GAINESVILLE, Fla. and CAMBRIDGE, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced next steps in the clinical development of the Company's potential treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene following receipt of written feedback from the FDA. The revised development plan, which includes immediate…

    FDA feedback allows for forward program development

    Company reiterates that its favorable safety profile and its advanced manufacturing and analytics capabilities enable rapid clinical development

    GAINESVILLE, Fla. and CAMBRIDGE, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced next steps in the clinical development of the Company's potential treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene following receipt of written feedback from the FDA. The revised development plan, which includes immediate expansion of the current trial in parallel with the planned Phase 2/3 trial, will be designed to evaluate sustained efficacy across multiple measures of potential benefit in patients with XLRP. 

    In lieu of an in-person meeting likely due to limitations imposed by COVID-19, the FDA provided comprehensive written feedback regarding the design and execution of a registration trial and future regulatory submissions. The Company continues to move forward as planned with manufacturing, clinical site preparation and other activities to enable initiation of the studies as quickly as possible. 

    "We are pleased with the productive feedback from the FDA and are modifying our development program based on their recommendations to advance our XLRP gene therapy candidate," said Sue Washer, President and CEO of AGTC. "Based on data available to date, we believe we have the potential for a best-in-class product when important factors such as visual sensitivity improvements, BCVA and safety are considered, which could provide meaningful benefit to patients with XLRP who today have no treatment options."

    AGTC is expanding its ongoing Phase 1/2 trial immediately and plans to dose approximately 20 patients in two masked dosing arms to collect additional functional data, including a mobility test added as a supplemental endpoint. The Company expects to begin dosing in Q4 2020.   

    For late stage studies, the FDA has indicated in its written feedback, which is consistent with how others in the XLRP gene therapy space are analyzing data, that a change in visual sensitivity of 7 decibels or greater in at least 5 loci would be clinically meaningful. AGTC has previously reported visual sensitivity as a mean over an entire treated area, but believes multiple patients already evaluated in the ongoing Phase 1/2 trial would meet the FDA's definition. The Company's revised Phase 2/3 trial design is also expected to include two masked active arms in addition to a control group, with visual sensitivity as the primary endpoint and several supplemental endpoints such as the mobility test.  AGTC expects to begin this trial in Q1 2021.

    Further information on the protocols for these trials including patient numbers, timelines and corporate cash guidance will be provided in the Company's 10K filing for the fiscal year ending June 30, 2020. In addition, AGTC remains on track to provide multiple data readouts for both its XLRP and ACHM clinical programs in the second half of 2020.  These readouts will include data from the two higher dose groups in the XLRP Phase 1/2 trial.

    About AGTC

    AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. Initially focusing on ophthalmology, our goal is to preserve or, hopefully, be able to improve vision in some cases. AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 & ACHM CNGA3). Our pre-clinical programs build on our industry leading AAV manufacturing technology and expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

    About X-linked Retinitis Pigmentosa (XLRP)

    XLRP is an inherited condition that causes progressive vision loss in boys and young men. Characteristics of the disease include night blindness in early childhood and progressive constriction of the visual field. In general, XLRP patients experience a gradual decline in visual acuity over the disease course, which results in legal blindness around the 4th decade of life. AGTC was granted U.S. Food and Drug Administration (FDA) orphan drug designation in 2017, as well as European Commission orphan medicinal product designation in 2016, for its gene therapy product candidate to treat XLRP caused by mutations in the RPGR gene.

    Forward-Looking Statements

    This release contains forward-looking statements that reflect AGTC's plans, estimates, assumptions and beliefs, including statements regarding the timing for and expected expansion of its XLRP clinical development program, the timing for reporting data in its XLRP and ACHM clinical programs, and its ability to enroll patients, effectively design and successfully complete its ongoing clinical trials. Forward-looking statements include information concerning possible or assumed preclinical and clinical product development and regulatory progress, future results of operations, financial guidance, business strategies and operations, potential growth opportunities, potential market opportunities, the effects of competition and the impact of the COVID-19 pandemic.  Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" or similar expressions and the negatives of those terms. Actual results could differ materially from those discussed in the forward-looking statements, due to a number of important factors. Risks and uncertainties that may cause actual results to differ materially include, among others: gene therapy is still novel with only a few approved treatments so far; AGTC cannot predict when or if it will obtain regulatory approval to commercialize a product candidate or receive reasonable reimbursement; uncertainty inherent in clinical trials and the regulatory review process; risks and uncertainties associated with drug development and commercialization; the direct and indirect impacts of the ongoing COVID-19 pandemic on the Company's business, results of operations, and financial condition; factors that could cause actual results to differ materially from those described in the forward-looking statements are set forth under the heading "Risk Factors" in the Company's most recent annual or quarterly report and in other reports AGTC has filed with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent management's plans, estimates, assumptions and beliefs only as of the date of this release. Except as required by law, AGTC assumes no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

    IR/PR CONTACTS: 

    David Carey (IR) or Glenn Silver (PR)

    Lazar FINN Partners

    T: (212) 867-1768 or (646) 871-8485

    or

    Corporate Contact:

    Bill Sullivan

    Chief Financial Officer

    Applied Genetic Technologies Corporation

    T: (617) 843-5728

    Stephen Potter

    Chief Business Officer

    Applied Genetic Technologies Corporation

    T: (617) 413-2754

    Primary Logo

    View Full Article Hide Full Article
  5. GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that the Company will be added to the Russell 3000® and 2000® Indexes, effective after the U.S. market opens on June 29, 2020, according to a preliminary list of additions posted on June 5.

    "We believe our addition to the Russell 3000 and 2000 Indexes validates the significant progress we have made in advancing our ongoing clinical programs in X-linked retinitis pigmentosa and achromatopsia," said Sue Washer, President and CEO of AGTC. "In 2020, we already…

    GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that the Company will be added to the Russell 3000® and 2000® Indexes, effective after the U.S. market opens on June 29, 2020, according to a preliminary list of additions posted on June 5.

    "We believe our addition to the Russell 3000 and 2000 Indexes validates the significant progress we have made in advancing our ongoing clinical programs in X-linked retinitis pigmentosa and achromatopsia," said Sue Washer, President and CEO of AGTC. "In 2020, we already announced positive data and completed enrollment in our XLRP trial, reported encouraging preliminary signs of biologic activity and completed adult enrollment in both ACHM trials, and strengthened our balance sheet with a successful financing. Our inclusion to the Russell Indexes represents an opportunity to further increase our visibility and exposure among a broader and growing group of institutional investors as we remain on track to provide multiple data readouts for our XLRP and ACHM clinical programs in the second half of 2020."

    Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

    For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.

    About AGTC

    AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. Initially focusing on ophthalmology, our goal is to preserve or, hopefully, be able to improve vision in some cases. AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 & ACHM CNGA3). Our pre-clinical programs build on our industry leading AAV manufacturing technology and expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

    About FTSE Russell

    FTSE Russell is a leading global index provider creating and managing a wide range of indexes, data and analytic solutions to meet client needs across asset classes, style and strategies. Covering 98% of the investable market, FTSE Russell indexes offer a true picture of global markets, combined with the specialist knowledge gained from developing local benchmarks around the world.

    FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $16 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create investment funds, ETFs, structured products and index-based derivatives. FTSE Russell indexes also provide clients with tools for asset allocation, investment strategy analysis and risk management.

    A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on index innovation and customer partnership applying the highest industry standards and embracing the IOSCO Principles. FTSE Russell is wholly owned by London Stock Exchange Group.

    For more information, visit www.ftserussell.com

    Forward-Looking Statements

    This release contains forward-looking statements that reflect AGTC's plans, estimates, assumptions and beliefs. Forward-looking statements include information concerning possible or assumed future results of operations, financial guidance, business strategies and operations, preclinical and clinical product development and regulatory progress, potential growth opportunities, potential market opportunities, the effects of competition and the impact of the COVID-19 pandemic. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" or similar expressions and the negatives of those terms. Actual results could differ materially from those discussed in the forward-looking statements, due to a number of important factors. Risks and uncertainties that may cause actual results to differ materially include, among others: gene therapy is still novel with only a few approved treatments so far; AGTC cannot predict when or if it will obtain regulatory approval to commercialize a product candidate or receive reasonable reimbursement; uncertainty inherent in clinical trials and the regulatory review process; risks and uncertainties associated with drug development and commercialization; the direct and indirect impacts of the ongoing COVID-19 pandemic on our business, results of operations, and financial condition; factors that could cause actual results to differ materially from those described in the forward-looking statements are set forth under the heading "Risk Factors" in our most recent annual or quarterly report and in other reports we have filed with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent management's plans, estimates, assumptions and beliefs only as of the date of this release. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

    IR/PR CONTACTS: 

    David Carey (IR) or Glenn Silver (PR)

    Lazar FINN Partners

    T: (212) 867-1768 or (646) 871-8485

    or

    Corporate Contact:

    Bill Sullivan

    Chief Financial Officer

    Applied Genetic Technologies Corporation

    T: (617) 843-5728

    Stephen Potter

    Chief Business Officer

    Applied Genetic Technologies Corporation

    T: (617) 413-2754

    Primary Logo

    View Full Article Hide Full Article
View All Applied Genetic Technologies Corporation News